Fosun Pharma Unit Wins Clinical Trial Approval for SRT-003-1 Diagnostic Drug

Stock News
昨天

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196.SH) announced that its controlling subsidiary, Chengdu Xingrui Jingxuan Biotechnology Co., Ltd., has received approval from the National Medical Products Administration to conduct clinical trials of [18F]F-SR031 injection, also known as SRT-003-1, for positron emission tomography (PET) imaging of fibroblast activation protein (FAP)-positive lesions in patients with solid tumors.

The subsidiary plans to initiate a Phase I clinical study of the drug in China once conditions permit.

SRT-003-1 is a radioactive in vivo diagnostic agent targeting fibroblast activation protein (FAP), intended primarily for PET imaging of FAP-positive lesions in solid tumor patients. FAP is a type II transmembrane serine protease belonging to the prolyl oligopeptidase family. It is barely expressed in normal tissues but is selectively overexpressed in cancer-associated fibroblasts (CAFs) of various epithelial tumors, including gastric cancer, esophageal cancer, lung cancer, colorectal cancer, and ovarian cancer. FAP inhibitors labeled with fluorine-18F can specifically bind to FAP on the surface of CAFs, causing FAP-overexpressing tumor lesions to show high uptake on PET imaging, thereby enabling tumor diagnosis, staging, and efficacy evaluation.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10